Advanced Prostate Cancer VL

Genetic Evaluation and Counseling in Prostate Cancer Treatment - Interview with Heather Cheng

(Length of Discussion: 16 min) An emerging expert in the field of genetics and prostate cancer, Heather Cheng speaks with Charles Ryan in a thought-provoking dialogue of genetic evaluation and counseling for patients with prostate cancer. They review a variety of the genes that are involved in both DNA repair as well as the Lynch Syndrome, wrapping up with a discussion about PARP Inhibitors. Biogr...

Optimizing Care in Patients with High Risk Prostate Cancer - Interview with Edward Schaeffer

(Length of Discussion: 10 min) Edward (Ted) Schaeffer, MD, Ph.D. and Alicia Morgans, MD share a dynamic discussion on the risk strategy that may be employed for high-risk prostate cancer patients including oligometastatic disease. They share observations such as an increase in patient volume in their clinics of men with rising PSAs, high grade and locally advanced disease. In discussing the best w...

Use of Conservative Management for Low-Risk Prostate Cancer - Interview with Stacy Loeb

(Length of Discussion: 7 min) Stacy Loeb, MD, and Alicia Morgans, MD discuss conservative management, active surveillance, and management trends over time for low-risk prostate cancer in the Veterans Affairs Integrated Health Care System over the past decade. Biographies: Stacy Loeb, MD, is an Assistant Professor of Urology and Population Health at New York University (NYU), specializing in prosta...

Long-Term Outcomes of Active Surveillance for Prostate Cancer - Interview with Sigrid Carlsson

Sigrid Carlsson, MD talks with Alicia Morgans, MD about long-term outcomes of active surveillance for prostate cancer, a 17-year experience with active surveillance at the Memorial Sloan Kettering Cancer Center. A study which Carlsson was a co-author on and was presented at the most recent American Urological Association meeting (AUA2018). This was a retrospective analysis of all patients managed...

Dedication to Multidisciplinary Management of GU Oncology - Alex Kutikov

(Length of Conversation: 10 min) Alex Kutikov, MD, FACS talks with Alicia Morgans, MD, MPH on the multidisciplinary management of genitourinary oncology and his experiences at Fox Chase Cancer Center. This discussion includes the importance of the collaborative care for the patient from the radiation oncologist, medical oncologist, and urologist and the nuances of this co-management with the numbe...

Clinical Implications of the Abi Race Study: Interview with Dan George

(Length of Discussion: 12 min) Daniel George, MD talks with Charles Ryan, MD and discusses a number of recent studies Daniel and his colleagues at Duke University School of Medicine have been focused on related to race and abiraterone outcomes in prostate cancer patients and how this new information impacts clinical practice. Studies and Presentations Discussed in Discussion: Overall Survival Betw...

The Men’s Eating and Living (MEAL) Study, Diet Intervention in Men on Active Surveillance for Prostate Cancer - Interview with J. Kellogg Parsons

(Length of Conversation: 22 mins) Download slides J. Kellogg Parsons MD, talks with Alicia Morgans prior to his presentation of The Men’s Eating and Living (MEAL) Study (CALGB 70807 [Alliance]): A Randomized Clinical Trial of a Diet Intervention in Men on Active Surveillance for Prostate Cancer at the 113th Annual Scientific Meeting of the American Urological Association (AUA) . A much anticipated...

The RADICAL PC Project - Jehonathan Pinthus

(Length of Presentation: 20 min) Jehonathan Pinthus presents the role of androgen deprivation therapy (ADT) in promoting cardiovascular disease (CVD) and focuses on two prospective studies, one of which is embedded in the other. The Role of Androgen Deprivation Therapy in Cardiovascular Disease – A Longitudinal Prostate Cancer Study (RADICAL PC1) is a prospective cohort study of men within one yea...

New Concepts in ADT- Thomas Keane

(Length of Discussion: 21 min) Tom Keane brings new concepts in androgen deprivation therapy (ADT) to light specifically discussing agonists versus antagonists, new androgen receptor-targeted drugs, including immunotherapy biomarkers, and genomic testing. He reviews the current state of the CRPC treatment and ADT options for use in advanced metastatic disease and concludes with a discussion on tre...

Quality of Life During Treatment with Chemohormonal Therapy - Alicia Morgans

(Length of Conversation: 7 min) Alicia Morgans, MD and Charles Ryan, MD discuss the quality of life between patients with metastatic hormone-sensitive prostate cancer who were treated with ADT+docetaxel and those who were treated with ADT alone. The importance of the study was to understand how different treatments actually affected the individuals receiving them. Biographies: Alicia Morgans, MD,...

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.